167 related articles for article (PubMed ID: 38066224)
21. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in
Wen Y; Ouyang D; Chen Q; Zeng L; Luo N; He H; Anwar M; Qu L; Zou Q; Yi W
Gland Surg; 2022 Jan; 11(1):100-114. PubMed ID: 35242673
[TBL] [Abstract][Full Text] [Related]
23. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
24. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
[TBL] [Abstract][Full Text] [Related]
25. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
26. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
27. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
28. Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients.
Shen HY; Xu JL; Zhu Z; Xu HP; Liang MX; Xu D; Chen WQ; Tang JH; Fang Z; Zhang J
Neoplasia; 2023 Nov; 45():100942. PubMed ID: 37839160
[TBL] [Abstract][Full Text] [Related]
29. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
[TBL] [Abstract][Full Text] [Related]
30. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
Lu X; Gao C; Liu C; Zhuang J; Su P; Li H; Wang X; Sun C
Pathol Res Pract; 2019 Aug; 215(8):152475. PubMed ID: 31178227
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
32. Prediction of prognosis and immunotherapy response in breast cancer based on neutrophil extracellular traps-related classification.
Zhao J; Xie X
Front Mol Biosci; 2023; 10():1165776. PubMed ID: 37304069
[TBL] [Abstract][Full Text] [Related]
33. GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis.
Zeng J; Yi J; Tan S; Zeng Y; Zou L; Zhang C; Liu L; Yi P; Fan P; Yu J
Front Endocrinol (Lausanne); 2022; 13():995972. PubMed ID: 36246907
[TBL] [Abstract][Full Text] [Related]
34. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
35. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
36. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
37. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
38. CD1C is associated with breast cancer prognosis and immune infiltrates.
Chen X; Zhang J; Lei X; Yang L; Li W; Zheng L; Zhang S; Ding Y; Shi J; Zhang L; Li J; Tang T; Jia W
BMC Cancer; 2023 Feb; 23(1):129. PubMed ID: 36755259
[TBL] [Abstract][Full Text] [Related]
39. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.
Li C; Zhang Y
BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644
[TBL] [Abstract][Full Text] [Related]
40. Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
Ye Y; Luo Y; Guo T; Zhang C; Sun Y; Xu A; Ji L; Ou J; Wu SY
Front Endocrinol (Lausanne); 2023; 14():1179050. PubMed ID: 37600707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]